ADB-BUTINACA

Synthetic cannabinoid

ADB-BUTINACA
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number	1185887-21-1
PubChem	119025000
DrugBank
ChemSpider	52085400
KEGG

ADB-BUTINACA is a synthetic cannabinoid that has been used as a designer drug. It is a potent agonist of the cannabinoid receptors, which are part of the endocannabinoid system in the human body.

Chemical Structure and Properties

Chemical structure of ADB-BUTINACA

ADB-BUTINACA is chemically classified as an indazole-based synthetic cannabinoid. Its IUPAC name is N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-butyl-1H-indazole-3-carboxamide. The compound has a molecular formula of C₁₈H₂₆N₄O₂ and a molecular weight of 330.43 g/mol.

The structure of ADB-BUTINACA includes an indazole core, which is a bicyclic structure consisting of a benzene ring fused to a pyrazole ring. The compound also features a butyl chain and a carboxamide group, which are common structural motifs in synthetic cannabinoids.

Pharmacology

ADB-BUTINACA acts as a potent agonist at the CB1 receptor and CB2 receptor, which are the primary receptors of the endocannabinoid system. These receptors are involved in a variety of physiological processes, including pain sensation, mood regulation, and appetite control.

The binding affinity of ADB-BUTINACA to these receptors is significantly higher than that of tetrahydrocannabinol (THC), the primary psychoactive component of cannabis. This high affinity contributes to the potent effects of ADB-BUTINACA, which can include both desired effects such as euphoria and relaxation, as well as adverse effects like anxiety, paranoia, and hallucinations.

Legal Status

Due to its potent effects and potential for abuse, ADB-BUTINACA has been classified as a controlled substance in many jurisdictions. It is often included in legislation targeting synthetic cannabinoids and other novel psychoactive substances (NPS).

Health Risks and Toxicity

The use of ADB-BUTINACA has been associated with a range of adverse health effects. These can include cardiovascular issues, such as increased heart rate and blood pressure, as well as neurological effects like seizures and loss of consciousness. The long-term health effects of ADB-BUTINACA use are not well understood, but the acute toxicity can be severe and potentially life-threatening.

Related Pages

• Synthetic cannabinoids
• Cannabinoid receptor
• Designer drug
• Novel psychoactive substances